Case Report: Marchiafava-Bignami disease: anti-parietal cell antibodies as a potential etiological factor in a novel case presentation
Abstract
Marchiafava-Bignami disease (MBD) represents a rare neurological disorder predominantly associated with chronic ethanol consumption and thiamine insufficiency. However, its possible correlation with cobalamin deficiency resulting from anti-parietal cell antibodies (APCA) remained inadequately characterized in the literature. Timely diagnosis and therapeutic intervention were critical for optimizing clinical outcomes. This case suggested that APCA screening and vitamin B12 assessment should be considered in the diagnostic workup of MBD, especially in patients without classic thiamine deficiency.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Metabolic Syndrome: Updates on Pathophysiology and Management in 2021
- Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases
- Antioxidants, inflammation and cardiovascular disease
- Application of Metabolomics in Alzheimer’s Disease
- Nutritional Importance of Carotenoids and Their Effect on Liver Health: A Review
- Nutritional essentiality of sulfur in health and disease
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.